Skip to main content
PharmaResources (Shanghai) Co., Ltd. logo

PharmaResources (Shanghai) Co., Ltd. — Investor Relations & Filings

Ticker · 301230 ISIN · CNE1000065Q9 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 458 across all filing types
Latest filing 2023-10-27 Share Issue/Capital Cha…
Country CN China
Listing Shenzhen Stock Exchange 301230

About PharmaResources (Shanghai) Co., Ltd.

https://www.pharmaresources.cn

PharmaResources (Shanghai) Co., Ltd. is a comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecule drug discovery and development. The company provides an integrated platform of services including medicinal chemistry, custom synthesis, process research and development, and analytical chemistry. PharmaResources supports global pharmaceutical and biotechnology partners through the entire drug development lifecycle, from initial lead optimization to the commercial-scale manufacturing of advanced intermediates and Active Pharmaceutical Ingredients (APIs). With a focus on technical innovation and quality management, the firm utilizes advanced synthetic methodologies and process engineering to accelerate drug candidates toward clinical trials and market approval.

Recent filings

Filing Released Lang Actions
关于首次公开发行前已发行的部分股份及首次公开发行战略配售股份上市流通提示性公告
Share Issue/Capital Change Classification · 95% confidence The document is a detailed announcement regarding the lifting of restrictions on certain shares that were issued before the company's initial public offering (IPO) and strategic placement shares related to the IPO. It includes specifics about the number of shares, shareholders involved, lock-up periods, and the date when these shares will become tradable. The document references regulatory approvals and compliance with stock exchange rules. It is not a financial report, earnings release, or management discussion, but rather a formal notification about share unlocking and listing for trading. This fits the definition of a Share Issue/Capital Change (SHA) filing, as it concerns changes in share capital availability and trading status post-IPO. The document length and content confirm it is not merely an announcement of a report but a substantive disclosure about share capital changes.
2023-10-27 Chinese
2023年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "上海泓博智源医药股份有限公司2023 年第三季度报告" which translates to "Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. 2023 Third Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, shareholder information, and notes on non-recurring gains and losses. The report explicitly states it is a quarterly report for the third quarter of 2023 and includes comprehensive financial statements and analysis for this period. The length of the document (15,000 characters) and the presence of substantive financial data confirm it is not merely an announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). 9M 2023
2023-10-25 Chinese
第三届董事会第十二次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the 12th meeting of the third board of directors of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It includes details about the board meeting, attendance, and voting results on two main agenda items: approval of the 2023 third quarter report and adjustment of the audit committee members. The document references the 2023 third quarter report but does not contain the report itself or detailed financial data. It also mentions that the full report is available on an external website. The document is primarily a formal announcement of board decisions and meeting outcomes, not the financial report or detailed management discussion. Therefore, it fits best under Board/Management Information (MANG) as it relates to board meeting resolutions and committee changes.
2023-10-25 Chinese
关于调整第三届董事会审计委员会委员的公告
Board/Management Information Classification · 100% confidence The document is an announcement from Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. regarding the adjustment of members of the third board of directors' audit committee. It details the resignation of a committee member and the election of a new member, referencing compliance with relevant laws and governance rules. There is no financial data, no mention of a report being published or attached, and the content focuses on board committee membership changes. This fits the category of Board/Management Information (MANG). The document length is short and it is a formal announcement of management changes, not a full report or financial disclosure.
2023-10-25 Chinese
第三届监事会第八次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board regarding the approval of the company's 2023 third quarter report. It states that the Supervisory Board has reviewed and approved the 2023 Q3 report, confirming its compliance and accuracy. However, the document itself does not contain the actual financial statements or substantive financial data of the quarterly report; it only announces the approval and refers readers to the full report available elsewhere. The document length is short (889 characters), and it serves as an announcement of the report's approval rather than the report itself. According to the 'Menu vs Meal' rule, this is not the quarterly report but an announcement related to it. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback for such announcements that do not contain the full report data.
2023-10-25 Chinese
中信证券股份有限公司关于上海泓博智源医药股份有限公司2023年半年度跟踪报告
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2023 年半年度跟踪报告' which translates to '2023 Half-Year Tracking Report' for Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It is prepared by CITIC Securities Co., Ltd. The content includes detailed oversight and supervision activities related to the company, including information disclosure review, internal control, fundraising supervision, governance, and regulatory compliance. It also discusses issues found and measures taken, company and shareholder commitments, and other matters such as regulatory sanctions and disciplinary actions. The document contains substantive financial and operational oversight information for a half-year period, indicating it is a comprehensive interim report rather than a brief announcement or a simple regulatory filing. The length is about 4932 characters, which is sufficient for a detailed report. Therefore, this document fits the definition of an Interim / Quarterly Report (IR) as it covers a period shorter than a full fiscal year with substantive data and analysis. H1 2023
2023-09-13 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.